Cognitive Bias Modification (CBM) and Internet Cognitive Behavioural Therapy (iCBT) for Depression- A Randomised Controlled Trial

Depression Clinical Trial

Official title:

A Randomised Controlled Trial Comparing Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder Plus a Cognitive Bias Modification Intervention (OxIGen) vs. Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder vs. a Waitlist Control on Symptoms of Depression and Negative Interpretation Bias.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01488058
• Other study ID #: 11/055
• Secondary ID: ACTRN12611001221
• Status: Completed
• Phase: N/A
• First received: December 5, 2011
• Last updated: September 18, 2012
• Start date: December 2011
• Est. completion date: August 2012

Study information

• Verified date: September 2012
• Source: St Vincent's Hospital, Sydney
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Human Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Cognitive accounts of depression and anxiety emphasize the importance of cognitive biases in the maintenance of disorders. One specific bias is the interpretation of ambiguous information. A negative interpretation bias is defined as a systematic tendency to interpret potentially ambiguous information in a negative rather than benign way and this bias has been associated with symptoms of depression. Research has led to the recent development of computerized cognitive bias modification (CBM) techniques to augment such biases and it has been suggested that CBM techniques may be useful as an adjunct to current treatments to enhance maintenance of treatment gains and minimize relapse rates. The fact that CBM procedures lend themselves to being delivered remotely, are cost-effective, and can be self-paced in ways that suit the patient make them an ideal candidate for inclusion in the Internet-based cognitive behavioural therapy (iCBT) programs currently offered through St. Vincent's Hospital and the University of New South Wales. Therefore, the primary aim of the current trial is to evaluate the acceptability and effectiveness of adding CBM procedures to the existing iCBT modules offered through St. Vincent's Hospital and the University of New South Wales. It is expected that iCBT + CBM will result in superior treatment outcomes as indexed by a standardized clinical battery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Meet Diagnostic and Statistical Manual of the American Psychiatric Association - 4th edition (DSM-IV) criteria for Major Depressive Disorder,

• Internet access + printer access,

• Australian resident,

• Fluent in written and spoken English.

Exclusion Criteria:

• Current substance abuse/dependence,

• Psychotic mental illness (Bipolar or Schizophrenia),

• Current or planned psychological treatment during study duration,

• Change in medication during last 1 month or intended change during study duration,

• Use of Benzodiazepines,

• Suicidal.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder

Intervention

Other:
• OxIGen + iCBT
OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
• Waitlist Control
Waitlist will receive iCBT at week 11

Locations

Country	Name	City	State
Australia	St. Vincent's Hospital	Darlinghurst	New South Wales

Sponsors (2)

Lead Sponsor	Collaborator
Alishia Williams	The University of New South Wales

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in score on the Beck Depression Inventory - second edition (BDI-II).		Administered at baseline, post-intervention (1 week), and post treatment (iCBT; 11 weeks)	No
Secondary	Change on the Scrambled Sentences Task (SST)- electronic version.		Administered at baseline, post-intervention (1 week).	No
Secondary	Change on Prospective Imagery Test (PIT).		Administered at baseline, post-intervention (1 week).	No
Secondary	Change on the Kessler-10 (K10).		Administered at baseline, before each iCBT lesson, and post-treatment (week 11).	No
Secondary	Change on WHO Disability Assessment Scale (WHO-DAS).		Administered baseline and post-treatment (iCBT; 11 weeks).	No
Secondary	Change on the Repetitive Thinking Questionnaire (RTQ).		Administered at baseline, post intervention (week 1), and post-treatment (iCBT; 11 weeks).	No
Secondary	Change on the State Trait Anxiety Inventory (STAI).		Administered at baseline, post intervention (week 1), and post-treatment (iCBT; 11 weeks).	No
Secondary	Change on the Ambiguous Sentence Task (AST).		Administered at baseline and post-intervention (week 1).	No
Secondary	Change in score on the Patient Health Questionnaire-9 (PHQ-9).		Administered at baseline, post intervention (week 1), and post treatment (week 11).	No